

LEGISLATURE OF NEBRASKA  
ONE HUNDRED FIFTH LEGISLATURE  
SECOND SESSION

**LEGISLATIVE BILL 906**

FINAL READING

Introduced by Williams, 36; Krist, 10.

Read first time January 08, 2018

Committee: Judiciary

1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to  
2 amend section 28-405, Revised Statutes Supplement, 2017; to change  
3 provisions relating to the schedules of controlled substances; and  
4 to repeal the original section.

5 Be it enacted by the people of the State of Nebraska,

1 Section 1. Section 28-405, Revised Statutes Supplement, 2017, is  
2 amended to read:

3 28-405 The following are the schedules of controlled substances  
4 referred to in the Uniform Controlled Substances Act, unless specifically  
5 contained on the list of exempted products of the Drug Enforcement  
6 Administration of the United States Department of Justice as the list  
7 existed on November 9, 2017:

8 Schedule I

9 (a) Any of the following opiates, including their isomers, esters,  
10 ethers, salts, and salts of isomers, esters, and ethers, unless  
11 specifically excepted, whenever the existence of such isomers, esters,  
12 ethers, and salts is possible within the specific chemical designation:

- 13 (1) Acetylmethadol;
- 14 (2) Allylprodine;
- 15 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also  
16 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
- 17 (4) Alphameprodine;
- 18 (5) Alphamethadol;
- 19 (6) Benzethidine;
- 20 (7) Betacetylmethadol;
- 21 (8) Betameprodine;
- 22 (9) Betamethadol;
- 23 (10) Betaprodine;
- 24 (11) Clonitazene;
- 25 (12) Dextromoramide;
- 26 (13) Difenoxyin;
- 27 (14) Diampromide;
- 28 (15) Diethylthiambutene;
- 29 (16) Dimenoxadol;
- 30 (17) Dimepheptanol;
- 31 (18) Dimethylthiambutene;

- 1 (19) Dioxaphetyl butyrate;
- 2 (20) Dipipanone;
- 3 (21) Ethylmethylthiambutene;
- 4 (22) Etonitazene;
- 5 (23) Etoxeridine;
- 6 (24) Furethidine;
- 7 (25) Hydroxypethidine;
- 8 (26) Ketobemidone;
- 9 (27) Levomoramide;
- 10 (28) Levophenacymorphan;
- 11 (29) Morpheridine;
- 12 (30) Noracymethadol;
- 13 (31) Norlevorphanol;
- 14 (32) Normethadone;
- 15 (33) Norpipanone;
- 16 (34) Phenadoxone;
- 17 (35) Phenampromide;
- 18 (36) Phenomorphan;
- 19 (37) Phenoperidine;
- 20 (38) Piritramide;
- 21 (39) Proheptazine;
- 22 (40) Properidine;
- 23 (41) Propiram;
- 24 (42) Racemoramide;
- 25 (43) Trimeperidine;
- 26 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
- 27 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
- 28 piperidine;
- 29 (45) Tilidine;
- 30 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
- 31 phenylpropanamide, its optical and geometric isomers, salts, and salts of

1 isomers;

2 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical  
3 isomers, salts, and salts of isomers;

4 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its  
5 optical isomers, salts, and salts of isomers;

6 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-  
7 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of  
8 isomers;

9 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-  
10 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts  
11 of isomers;

12 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,  
13 its optical isomers, salts, and salts of isomers;

14 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-  
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts  
16 of isomers;

17 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-  
18 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and  
19 geometric isomers, salts, and salts of isomers;

20 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-  
21 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,  
22 salts, and salts of isomers;

23 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
24 (thenylfentanyl), its optical isomers, salts, and salts of isomers;

25 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-  
26 propanamide, its optical isomers, salts, and salts of isomers;

27 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-  
28 piperidinyl)propanamide, its optical isomers, salts, and salts of  
29 isomers; and

30 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-  
31 methylbenzamide.

1 (b) Any of the following opium derivatives, their salts, isomers,  
2 and salts of isomers, unless specifically excepted, whenever the  
3 existence of such salts, isomers, and salts of isomers is possible within  
4 the specific chemical designation:

- 5 (1) Acetorphine;
- 6 (2) Acetyldihydrocodeine;
- 7 (3) Benzylmorphine;
- 8 (4) Codeine methylbromide;
- 9 (5) Codeine-N-Oxide;
- 10 (6) Cyprenorphine;
- 11 (7) Desomorphine;
- 12 (8) Dihydromorphine;
- 13 (9) Drotebanol;
- 14 (10) Etorphine, except hydrochloride salt;
- 15 (11) Heroin;
- 16 (12) Hydromorphinol;
- 17 (13) Methyldesorphine;
- 18 (14) Methyldihydromorphine;
- 19 (15) Morphine methylbromide;
- 20 (16) Morphine methylsulfonate;
- 21 (17) Morphine-N-Oxide;
- 22 (18) Myrophine;
- 23 (19) Nicocodeine;
- 24 (20) Nicomorphine;
- 25 (21) Normorphine;
- 26 (22) Pholcodine; and
- 27 (23) Thebacon.

28 (c) Any material, compound, mixture, or preparation which contains  
29 any quantity of the following hallucinogenic substances, their salts,  
30 isomers, and salts of isomers, unless specifically excepted, whenever the  
31 existence of such salts, isomers, and salts of isomers is possible within

1 the specific chemical designation, and, for purposes of this subdivision  
2 only, isomer shall include the optical, position, and geometric isomers:

3 (1) Bufotenine. Trade and other names shall include, but are not  
4 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-  
5 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-  
6 dimethyltryptamine; and mappine;

7 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall  
8 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-  
9 methylphenethylamine; and 4-bromo-2,5-DMA;

10 (3) 4-methoxyamphetamine. Trade and other names shall include, but  
11 are not limited to: 4-methoxy-alpha-methylphenethylamine; and  
12 paramethoxyamphetamine, PMA;

13 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall  
14 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-  
15 methylphenethylamine; DOM; and STP;

16 (5) Ibogaine. Trade and other names shall include, but are not  
17 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-  
18 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe  
19 iboga;

20 (6) Lysergic acid diethylamide;

21 (7) Marijuana;

22 (8) Mescaline;

23 (9) Peyote. Peyote shall mean all parts of the plant presently  
24 classified botanically as *Lophophora williamsii* Lemaire, whether growing  
25 or not, the seeds thereof, any extract from any part of such plant, and  
26 every compound, manufacture, salts, derivative, mixture, or preparation  
27 of such plant or its seeds or extracts;

28 (10) Psilocybin;

29 (11) Psilocyn;

30 (12) Tetrahydrocannabinols, including, but not limited to, synthetic  
31 equivalents of the substances contained in the plant or in the resinous

1 extractives of cannabis, sp. or synthetic substances, derivatives, and  
2 their isomers with similar chemical structure and pharmacological  
3 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol  
4 and their optical isomers, excluding dronabinol ~~in sesame oil and~~  
5 ~~encapsulated in a soft gelatin capsule~~ in a drug product approved by the  
6 federal Food and Drug Administration; Delta 6 cis or trans  
7 tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis or  
8 trans tetrahydrocannabinol and its optical isomers. Since nomenclature of  
9 these substances is not internationally standardized, compounds of these  
10 structures shall be included regardless of the numerical designation of  
11 atomic positions covered;

12 (13) N-ethyl-3-piperidyl benzilate;

13 (14) N-methyl-3-piperidyl benzilate;

14 (15) Thiophene analog of phencyclidine. Trade and other names shall  
15 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;  
16 2-thienyl analog of phencyclidine; TPCP; and TCP;

17 (16) Hashish or concentrated cannabis;

18 (17) Parahexyl. Trade and other names shall include, but are not  
19 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-  
20 dibenzo(b,d)pyran; and Synhexyl;

21 (18) Ethylamine analog of phencyclidine. Trade and other names shall  
22 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-  
23 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;  
24 cyclohexamine; and PCE;

25 (19) Pyrrolidine analog of phencyclidine. Trade and other names  
26 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-  
27 pyrrolidine; PCPy; and PHP;

28 (20) Alpha-ethyltryptamine. Some trade or other names: etryptamine;  
29 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;  
30 alpha-ET; and AET;

31 (21) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

1 (22) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

2 (23) Alpha-methyltryptamine, which is also known as AMT;

3 (24) *Salvia divinorum* or Salvinorin A. *Salvia divinorum* or  
4 Salvinorin A includes all parts of the plant presently classified  
5 botanically as *Salvia divinorum*, whether growing or not, the seeds  
6 thereof, any extract from any part of such plant, and every compound,  
7 manufacture, derivative, mixture, or preparation of such plant, its  
8 seeds, or its extracts, including salts, isomers, and salts of isomers  
9 whenever the existence of such salts, isomers, and salts of isomers is  
10 possible within the specific chemical designation;

11 (25) Any material, compound, mixture, or preparation containing any  
12 quantity of synthetically produced cannabinoids as listed in subdivisions  
13 (A) through (L) of this subdivision, including their salts, isomers,  
14 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,  
15 unless specifically excepted elsewhere in this section. Since  
16 nomenclature of these synthetically produced cannabinoids is not  
17 internationally standardized and may continually evolve, these structures  
18 or compounds of these structures shall be included under this  
19 subdivision, regardless of their specific numerical designation of atomic  
20 positions covered, so long as it can be determined through a recognized  
21 method of scientific testing or analysis that the substance contains  
22 properties that fit within one or more of the following categories:

23 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally  
24 contained in a plant of the genus *cannabis* (*cannabis* plant), as well as  
25 synthetic equivalents of the substances contained in the plant, or in the  
26 resinous extractives of *cannabis*, sp. and/or synthetic substances,  
27 derivatives, and their isomers with similar chemical structure and  
28 pharmacological activity such as the following: Delta 1 cis or trans  
29 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans  
30 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans  
31 tetrahydrocannabinol, and its optical isomers;

1 (B) Naphthoylindoles: Any compound containing a 3-(1-  
2 naphthoyl)indole structure with substitution at the nitrogen atom of the  
3 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
4 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
5 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
6 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
7 tetrahydropyranylmethyl group, whether or not further substituted in or  
8 on any of the listed ring systems to any extent;

9 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-  
10 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom  
11 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
12 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
13 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
15 tetrahydropyranylmethyl group, whether or not further substituted in or  
16 on any of the listed ring systems to any extent;

17 (D) Naphthoylpyrroles: Any compound containing a 3-(1-  
18 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the  
19 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
20 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
21 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
22 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
23 tetrahydropyranylmethyl group, whether or not further substituted in or  
24 on any of the listed ring systems to any extent;

25 (E) Naphthylideneindenes: Any compound containing a  
26 naphthylideneindene structure with substitution at the 3-position of the  
27 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
28 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
29 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
30 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
31 tetrahydropyranylmethyl group, whether or not further substituted in or

1 on any of the listed ring systems to any extent;

2 (F) Phenylacetylindoles: Any compound containing a 3-  
3 phenylacetylindole structure with substitution at the nitrogen atom of  
4 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
5 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
6 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
7 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
8 tetrahydropyranylmethyl group, whether or not further substituted in or  
9 on any of the listed ring systems to any extent;

10 (G) Cyclohexylphenols: Any compound containing a 2-(3-  
11 hydroxycyclohexyl)phenol structure with substitution at the 5-position of  
12 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
13 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
14 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
15 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
16 tetrahydropyranylmethyl group, whether or not substituted in or on any of  
17 the listed ring systems to any extent;

18 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole  
19 structure with substitution at the nitrogen atom of the indole ring by an  
20 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,  
21 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-  
22 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
23 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not  
24 further substituted in or on any of the listed ring systems to any  
25 extent;

26 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole  
27 structure with substitution at the nitrogen atom of the indole ring by an  
28 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,  
29 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
30 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
31 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not

1 further substituted in or on any of the listed ring systems to any  
2 extent;

3 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-  
4 tetramethylcyclopropanoylindole structure with substitution at the  
5 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
6 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
7 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
8 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
9 tetrahydropyranylmethyl group, whether or not further substituted in or  
10 on any of the listed ring systems to any extent;

11 (K) Indole carboxamides: Any compound containing a 1-indole-3-  
12 carboxamide structure with substitution at the nitrogen atom of the  
13 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
14 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
15 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
17 tetrahydropyranylmethyl group, substitution at the carboxamide group by  
18 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
19 phenyl, aminoalkyl group, or quinolinyl group, whether or not further  
20 substituted in or on any of the listed ring systems to any extent or to  
21 the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or  
22 propionaldehyde groups to any extent;

23 (L) Indole carboxylates: Any compound containing a 1-indole-3-  
24 carboxylate structure with substitution at the nitrogen atom of the  
25 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
26 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
27 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
29 tetrahydropyranylmethyl group, substitution at the carboxylate group by  
30 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
31 phenyl, aminoalkyl group, or quinolinyl group, whether or not further

1 substituted in or on any of the listed ring systems to any extent or to  
2 the adamantyl, 1-maphthyl, phenyl, aminooxoalkyl, benzyl, or  
3 propionaldehyde groups to any extent; and

4 (M) Any nonnaturally occurring substance, chemical compound,  
5 mixture, or preparation, not specifically listed elsewhere in these  
6 schedules and which is not approved for human consumption by the federal  
7 Food and Drug Administration, containing or constituting a cannabinoid  
8 receptor agonist as defined in section 28-401;

9 (26) Any material, compound, mixture, or preparation containing any  
10 quantity of a substituted phenethylamine as listed in subdivisions (A)  
11 through (C) of this subdivision, unless specifically excepted, listed in  
12 another schedule, or specifically named in this schedule, that is  
13 structurally derived from phenylethan-2-amine by substitution on the  
14 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a  
15 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by  
16 substitution with one alkoxy and either one fused furan, tetrahydrofuran,  
17 or tetrahydropyran ring system; or by substitution with two fused ring  
18 systems from any combination of the furan, tetrahydrofuran, or  
19 tetrahydropyran ring systems, whether or not the compound is further  
20 modified in any of the following ways:

21 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,  
22 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-  
23 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen  
24 atom with alkyl, dialkyl, benzyl, hydroxybenzyl or methoxybenzyl groups,  
25 and including, but not limited to:

26 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known  
27 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;

28 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known  
29 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;

30 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known  
31 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;

- 1 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H  
2 or 2,5-Dimethoxyphenethylamine;
- 3 (v) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine, which is also known as  
4 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
- 5 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known  
6 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
- 7 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also  
8 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
- 9 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
10 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
- 11 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
12 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
- 13 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known  
14 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
- 15 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also  
16 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
- 17 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also  
18 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
- 19 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also  
20 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
- 21 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also  
22 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 23 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-  
24 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-  
25 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
- 26 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-  
27 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-  
28 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 29 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,  
30 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-  
31 methoxybenzyl)phenethylamine;

- 1 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-  
2 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or  
3 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 4 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,  
5 which is also known as 2CB-5-hemiFLY;
- 6 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-  
7 yl)ethanamine, which is also known as 2C-B-FLY;
- 8 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-  
9 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 10 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-  
11 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-  
12 NBOMe;
- 13 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,  
14 which is also known as bromo-benzodifuranylisopropylamine or bromo-  
15 dragonFLY;
- 16 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which  
17 is also known as 2C-INBOH or 25I-NBOH;
- 18 (xxv) 5-(2-Aminopropyl)benzofuran 5-(2-Aminoprpyl)benzofuran, which  
19 is also known as 5-APB;
- 20 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
- 21 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known  
22 as 5-APDB;
- 23 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also  
24 known as 6-APDB;
- 25 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-  
26 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
- 27 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
- 28 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also  
29 known as 2C-T-7;
- 30 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 31 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as

- 1 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
- 2 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
- 3 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
- 4 MDMA;
- 5 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
- 6 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA; and
- 7 (xxxvii) 3,4,5-trimethoxy amphetamine;
- 8 (27) Any material, compound, mixture, or preparation containing any
- 9 quantity of a substituted tryptamine unless specifically excepted, listed
- 10 in another schedule, or specifically named in this schedule, that is
- 11 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
- 12 known as tryptamine, by mono- or di-substitution of the amine nitrogen
- 13 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
- 14 in a cyclic structure whether or not the compound is further substituted
- 15 at the alpha position with an alkyl group or whether or not further
- 16 substituted on the indole ring to any extent with any alkyl, alkoxy,
- 17 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
- 18 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
- 19 DALT;
- 20 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
- 21 DMT or OAcetylpsilocin;
- 22 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
- 23 HO-MET;
- 24 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
- 25 HO-DIPT;
- 26 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
- 27 5-MeOMiPT;
- 28 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
- 29 DMT;
- 30 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
- 31 MeO-DiPT;

1 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,  
2 DET; and

3 (I) Dimethyltryptamine, which is also known as DMT; and

4 (28)(A) Any substance containing any quantity of the following  
5 materials, compounds, mixtures, or structures:

6 (i) 3,4-methylenedioxy methcathinone, or bk-MDMA, or methylone;

7 (ii) 3,4-methylenedioxy pyrovalerone, or MDPV;

8 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

9 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

10 (v) Fluoromethcathinone, or FMC;

11 (vi) Naphthylpyrovalerone, or naphyrone; or

12 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or  
13 butylone; or

14 (B) Unless listed in another schedule, any substance which contains  
15 any quantity of any material, compound, mixture, or structure, other than  
16 bupropion, that is structurally derived by any means from 2-  
17 aminopropan-1-one by substitution at the 1-position with either phenyl,  
18 naphthyl, or thiophene ring systems, whether or not the compound is  
19 further modified in any of the following ways:

20 (i) Substitution in the ring system to any extent with alkyl,  
21 alkoxy, alkylendioxy, haloalkyl, hydroxyl, or halide substituents,  
22 whether or not further substituted in the ring system by one or more  
23 other univalent substituents;

24 (ii) Substitution at the 3-position with an acyclic alkyl  
25 substituent; or

26 (iii) Substitution at the 2-amino nitrogen atom with alkyl or  
27 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic  
28 structure.

29 (d) Unless specifically excepted or unless listed in another  
30 schedule, any material, compound, mixture, or preparation which contains  
31 any quantity of the following substances having a depressant effect on

1 the central nervous system, including its salts, isomers, and salts of  
2 isomers whenever the existence of such salts, isomers, and salts of  
3 isomers is possible within the specific chemical designation:

4 (1) Mecloqualone;

5 (2) Methaqualone; and

6 (3) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-  
7 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium  
8 Oxybate; and Sodium Oxybutyrate.

9 (e) Unless specifically excepted or unless listed in another  
10 schedule, any material, compound, mixture, or preparation which contains  
11 any quantity of the following substances having a stimulant effect on the  
12 central nervous system, including its salts, isomers, and salts of  
13 isomers:

14 (1) Fenethylamine;

15 (2) N-ethylamphetamine;

16 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-  
17 dihydro-5-phenyl-2-oxazolamine;

18 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-  
19 aminopropiophenone; 2-aminopropiophenone; and norephedrone;

20 (5) Methcathinone, its salts, optical isomers, and salts of optical  
21 isomers. Some other names: 2-(methylamino)-propionophenone; alpha-  
22 (methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-  
23 N-methylaminopropionophenone; methylcathinone; monomethylpropion;  
24 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; and UR1432;

25 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-  
26 phenyl-2-oxazolamine;

27 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;  
28 and N,N-alpha-trimethylphenethylamine; and

29 (8) Benzylpiperazine, 1-benzylpiperazine.

30 (f) Any controlled substance analogue to the extent intended for  
31 human consumption.

1 Schedule II

2 (a) Any of the following substances except those narcotic drugs  
3 listed in other schedules whether produced directly or indirectly by  
4 extraction from substances of vegetable origin, independently by means of  
5 chemical synthesis, or by combination of extraction and chemical  
6 synthesis:

7 (1) Opium and opiate, and any salt, compound, derivative, or  
8 preparation of opium or opiate, excluding apomorphine, buprenorphine,  
9 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmeffene,  
10 naloxone, and naltrexone and their salts, but including the following:

- 11 (A) Raw opium;
- 12 (B) Opium extracts;
- 13 (C) Opium fluid;
- 14 (D) Powdered opium;
- 15 (E) Granulated opium;
- 16 (F) Tincture of opium;
- 17 (G) Codeine;
- 18 (H) Ethylmorphine;
- 19 (I) Etorphine hydrochloride;
- 20 (J) Hydrocodone;
- 21 (K) Hydromorphone;
- 22 (L) Metopon;
- 23 (M) Morphine;
- 24 (N) Oxycodone;
- 25 (O) Oxymorphone;
- 26 (P) Oripavine;
- 27 (Q) Thebaine; and
- 28 (R) Dihydroetorphine;

29 (2) Any salt, compound, derivative, or preparation thereof which is  
30 chemically equivalent to or identical with any of the substances referred  
31 to in subdivision (1) of this subdivision, except that these substances

1 shall not include the isoquinoline alkaloids of opium;

2 (3) Opium poppy and poppy straw;

3 (4) Coca leaves and any salt, compound, derivative, or preparation  
4 of coca leaves, and any salt, compound, derivative, or preparation  
5 thereof which is chemically equivalent to or identical with any of these  
6 substances, including cocaine or ecgonine and its salts, optical isomers,  
7 and salts of optical isomers, except that the substances shall not  
8 include decocainized coca leaves or extractions which do not contain  
9 cocaine or ecgonine; and

10 (5) Concentrate of poppy straw, the crude extract of poppy straw in  
11 either liquid, solid, or powder form which contains the phenanthrene  
12 alkaloids of the opium poppy.

13 (b) Unless specifically excepted or unless in another schedule any  
14 of the following opiates, including their isomers, esters, ethers, salts,  
15 and salts of their isomers, esters, and ethers whenever the existence of  
16 such isomers, esters, ethers, and salts is possible within the specific  
17 chemical designation, dextrorphan excepted:

18 (1) Alphaprodine;

19 (2) Anileridine;

20 (3) Bezitramide;

21 (4) Diphenoxylate;

22 (5) Fentanyl;

23 (6) Isomethadone;

24 (7) Levomethorphan;

25 (8) Levorphanol;

26 (9) Metazocine;

27 (10) Methadone;

28 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl  
29 butane;

30 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-  
31 diphenylpropane-carboxylic acid;

- 1 (13) Pethidine or meperidine;
- 2 (14) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 3 (15) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
- 4 carboxylate;
- 5 (16) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
- 6 carboxylic acid;
- 7 (17) Phenazocine;
- 8 (18) Piminodine;
- 9 (19) Racemethorphan;
- 10 (20) Racemorphan;
- 11 (21) Dihydrocodeine;
- 12 (22) Bulk Propoxyphene in nondosage forms;
- 13 (23) Sufentanil;
- 14 (24) Alfentanil;
- 15 (25) Levo-alphaacetylmethadol which is also known as levo-alpha-
- 16 acetylmethadol, levomethadyl acetate, and LAAM;
- 17 (26) Carfentanil;
- 18 (27) Remifentanil;~~and~~
- 19 (28) Tapentadol; and -
- 20 (29) Thiafentanil.

21 (c) Any material, compound, mixture, or preparation which contains  
22 any quantity of the following substances having a potential for abuse  
23 associated with a stimulant effect on the central nervous system:

- 24 (1) Amphetamine, its salts, optical isomers, and salts of its
- 25 optical isomers;
- 26 (2) Phenmetrazine and its salts;
- 27 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
- 28 (4) Methylphenidate; and
- 29 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.

30 (d) Any material, compound, mixture, or preparation which contains  
31 any quantity of the following substances having a potential for abuse

1 associated with a depressant effect on the central nervous system,  
2 including their salts, isomers, and salts of isomers whenever the  
3 existence of such salts, isomers, and salts of isomers is possible within  
4 the specific chemical designations:

- 5 (1) Amobarbital;
- 6 (2) Secobarbital;
- 7 (3) Pentobarbital;
- 8 (4) Phencyclidine; and
- 9 (5) Glutethimide.

10 (e) Hallucinogenic substances known as:

11 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-  
12 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-  
13 dibenzo(b,d)pyran-9-one; and -

14 (2) Dronabinol in an oral solution in a drug product approved by the  
15 federal Food and Drug Administration.

16 (f) Unless specifically excepted or unless listed in another  
17 schedule, any material, compound, mixture, or preparation which contains  
18 any quantity of the following substances:

19 (1) Immediate precursor to amphetamine and methamphetamine:  
20 Phenylacetone. Trade and other names shall include, but are not limited  
21 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
22 ketone;

23 (2) Immediate precursors to phencyclidine, PCP:

- 24 (A) 1-phenylcyclohexylamine; or
- 25 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or

26 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethyl-4-  
27 piperidine (ANNPP).

28 Schedule III

29 (a) Any material, compound, mixture, or preparation which contains  
30 any quantity of the following substances having a potential for abuse  
31 associated with a stimulant effect on the central nervous system,

1 including their salts, isomers, whether optical, position, or geometric,  
2 and salts of such isomers whenever the existence of such salts, isomers,  
3 and salts of isomers is possible within the specific chemical  
4 designation:

- 5 (1) Benzphetamine;
- 6 (2) Chlorphentermine;
- 7 (3) Clortermine; and
- 8 (4) Phendimetrazine.

9 (b) Any material, compound, mixture, or preparation which contains  
10 any quantity of the following substances having a potential for abuse  
11 associated with a depressant effect on the central nervous system:

12 (1) Any substance which contains any quantity of a derivative of  
13 barbituric acid or any salt of a derivative of barbituric acid, except  
14 those substances which are specifically listed in other schedules of this  
15 section;

- 16 (2) Chlorhexadol;
- 17 (3) Embutramide;
- 18 (4) Lysergic acid;
- 19 (5) Lysergic acid amide;
- 20 (6) Methyprylon;
- 21 (7) Perampanel;
- 22 (8) Sulfondiethylmethane;
- 23 (9) Sulfonethylmethane;
- 24 (10) Sulfonmethane;
- 25 (11) Nalorphine;

26 (12) Any compound, mixture, or preparation containing amobarbital,  
27 secobarbital, pentobarbital, or any salt thereof and one or more other  
28 active medicinal ingredients which are not listed in any schedule;

29 (13) Any suppository dosage form containing amobarbital,  
30 secobarbital, pentobarbital, or any salt of any of these drugs and  
31 approved by the federal Food and Drug Administration for marketing only

1 as a suppository;

2 (14) Any drug product containing gamma-hydroxybutyric acid,  
3 including its salts, isomers, and salts of isomers, for which an  
4 application is approved under section 505 of the Federal Food, Drug, and  
5 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;

6 (15) Ketamine, its salts, isomers, and salts of isomers. Some other  
7 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-  
8 cyclohexanone; and

9 (16) Tiletamine and zolazepam or any salt thereof. Trade or other  
10 names for a tiletamine-zolazepam combination product shall include, but  
11 are not limited to: telazol. Trade or other names for tiletamine shall  
12 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-  
13 cyclohexanone. Trade or other names for zolazepam shall include, but are  
14 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-  
15 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrzapon.

16 (c) Unless specifically excepted or unless listed in another  
17 schedule:

18 (1) Any material, compound, mixture, or preparation containing  
19 limited quantities of any of the following narcotic drugs, or any salts  
20 calculated as the free anhydrous base or alkaloid, in limited quantities  
21 as set forth below:

22 (A) Not more than one and eight-tenths grams of codeine per one  
23 hundred milliliters or not more than ninety milligrams per dosage unit,  
24 with an equal or greater quantity of an isoquinoline alkaloid of opium;

25 (B) Not more than one and eight-tenths grams of codeine per one  
26 hundred milliliters or not more than ninety milligrams per dosage unit,  
27 with one or more active, nonnarcotic ingredients in recognized  
28 therapeutic amounts;

29 (C) Not more than one and eight-tenths grams of dihydrocodeine per  
30 one hundred milliliters or not more than ninety milligrams per dosage  
31 unit, with one or more active, nonnarcotic ingredients in recognized

1 therapeutic amounts;

2 (D) Not more than three hundred milligrams of ethylmorphine per one  
3 hundred milliliters or not more than fifteen milligrams per dosage unit,  
4 with one or more active, nonnarcotic ingredients in recognized  
5 therapeutic amounts;

6 (E) Not more than five hundred milligrams of opium per one hundred  
7 milliliters or per one hundred grams, or not more than twenty-five  
8 milligrams per dosage unit, with one or more active, nonnarcotic  
9 ingredients in recognized therapeutic amounts; and

10 (F) Not more than fifty milligrams of morphine per one hundred  
11 milliliters or per one hundred grams with one or more active, nonnarcotic  
12 ingredients in recognized therapeutic amounts; and

13 (2) Any material, compound, mixture, or preparation containing any  
14 of the following narcotic drug or its salts, as set forth below:

15 (A) Buprenorphine.

16 (d) Unless contained on the list of exempt anabolic steroids of the  
17 Drug Enforcement Administration of the United States Department of  
18 Justice as the list existed on November 9, 2017 ~~January 1, 2014~~, any  
19 anabolic steroid, which shall include any material, compound, mixture, or  
20 preparation containing any quantity of the following substances,  
21 including its salts, isomers, and salts of isomers whenever the existence  
22 of such salts of isomers is possible within the specific chemical  
23 designation:

24 (1) 3-beta,17-dihydroxy-5a-androstane;

25 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;

26 (3) 5-alpha-androstan-3,17-dione;

27 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-  
28 ene);

29 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-  
30 ene);

31 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);

- 1 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
- 2 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
- 3 (9) 4-androstenedione (androst-4-en-3,17-dione);
- 4 (10) 5-androstenedione (androst-5-en-3,17-dione);
- 5 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
- 6 hydroxyandrost-4-en-3-one);
- 7 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
- 8 (13) Boldione (androsta-1,4-diene-3,17-3-one);
- 9 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
- 10 en-3-one);
- 11 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
- 12 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
- 13 alpha-methyl-androst-1,4-dien-3-one);
- 14 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
- 15 en-17-beta-ol) (a.k.a. 'madol');
- 16 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
- 17 hydroxy-5-alpha-androst-1-en-3-one);
- 18 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
- 19 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
- 20 androstan-3-one);
- 21 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
- 22 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
- 23 dihydroxyandrost-4-en-3-one);
- 24 (23) Formebolone (formebolone); (2-formyl-17-alpha-methyl-11-
- 25 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
- 26 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
- 27 furazan);
- 28 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
- 29 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
- 30 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
- 31 one);

- 1 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-  
2 one);
- 3 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-  
4 one);
- 5 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-  
6 dien-3-one);
- 7 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-  
8 ene);
- 9 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-  
10 beta-ol-3-one);
- 11 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-  
12 one);
- 13 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
- 14 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
- 15 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
- 16 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-  
17 hydroxy-17-beta-hydroxyestr-4-en-3-one);
- 18 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-  
19 dien-3-one);
- 20 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-  
21 trien-3-one);
- 22 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-  
23 en-3-one);
- 24 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-  
25 en-3-one);
- 26 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-  
27 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-  
28 methyl-1-testosterone');
- 29 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
- 30 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
- 31 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);

- 1 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
- 2 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
- 3 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
- 4 dione);
- 5 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 6 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 7 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
- 8 en-3-one);
- 9 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
- 10 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
- 11 one);
- 12 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
- 13 one);
- 14 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
- 15 androstan-3-one);
- 16 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
- 17 en-3-one);
- 18 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
- 19 hydroxy-[5-alpha]-androstan-3-one);
- 20 (58) Prostanazol (17-beta-hydroxy-5-alpha-androstano[3,2-
- 21 c]pyrazole);
- 22 (59) Stanazolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
- 23 androst-2-eno[3,2-c]-pyrazole);
- 24 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
- 25 one);
- 26 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
- 27 oic acid lactone);
- 28 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
- 29 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
- 30 hydroxygon-4,9,11-trien-3-one);
- 31 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one); and

1 (65) Any salt, ester, or ether of a drug or substance described or  
2 listed in this subdivision if the salt, ester, or ether promotes muscle  
3 growth.

4 (e) Hallucinogenic substances known as:

5 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft  
6 gelatin capsule in a drug product approved by the federal Food and Drug  
7 Administration. Some other names for dronabinol are (6aR-  
8 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo  
9 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

10 Schedule IV

11 (a) Any material, compound, mixture, or preparation which contains  
12 any quantity of the following substances, including their salts, isomers,  
13 and salts of isomers whenever the existence of such salts, isomers, and  
14 salts of isomers is possible within the specific chemical designation:

15 (1) Barbital;

16 (2) Chloral betaine;

17 (3) Chloral hydrate;

18 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide  
19 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and  
20 water soluble esterified estrogens);

21 (5) Clonazepam;

22 (6) Clorazepate;

23 (7) Diazepam;

24 (8) Ethchlorvynol;

25 (9) Ethinamate;

26 (10) Flurazepam;

27 (11) Mebutamate;

28 (12) Meprobamate;

29 (13) Methohexital;

30 (14) Methylphenobarbital;

31 (15) Oxazepam;

- 1 (16) Paraldehyde;
- 2 (17) Petrichloral;
- 3 (18) Phenobarbital;
- 4 (19) Prazepam;
- 5 (20) Alprazolam;
- 6 (21) Bromazepam;
- 7 (22) Camazepam;
- 8 (23) Clobazam;
- 9 (24) Clotiazepam;
- 10 (25) Cloxazolam;
- 11 (26) Delorazepam;
- 12 (27) Estazolam;
- 13 (28) Ethyl loflazepate;
- 14 (29) Fludiazepam;
- 15 (30) Flunitrazepam;
- 16 (31) Halazepam;
- 17 (32) Haloxazolam;
- 18 (33) Ketazolam;
- 19 (34) Loprazolam;
- 20 (35) Lorazepam;
- 21 (36) Lormetazepam;
- 22 (37) Medazepam;
- 23 (38) Nimetazepam;
- 24 (39) Nitrazepam;
- 25 (40) Nordiazepam;
- 26 (41) Oxazolam;
- 27 (42) Pinazepam;
- 28 (43) Temazepam;
- 29 (44) Tetrazepam;
- 30 (45) Triazolam;
- 31 (46) Midazolam;

- 1 (47) Quazepam;
- 2 (48) Zolpidem;
- 3 (49) Dichloralphenazone;
- 4 (50) Zaleplon;
- 5 (51) Zopiclone;
- 6 (52) Fospropofol;
- 7 (53) Alfaxalone;
- 8 (54) Suvorexant; and
- 9 (55) Carisoprodol.

10 (b) Any material, compound, mixture, or preparation which contains  
11 any quantity of the following substance, including its salts, isomers,  
12 whether optical, position, or geometric, and salts of such isomers,  
13 whenever the existence of such salts, isomers, and salts of isomers is  
14 possible: Fenfluramine.

15 (c) Unless specifically excepted or unless listed in another  
16 schedule, any material, compound, mixture, or preparation which contains  
17 any quantity of the following substances having a stimulant effect on the  
18 central nervous system, including their salts, isomers, whether optical,  
19 position, or geometric, and salts of such isomers whenever the existence  
20 of such salts, isomers, and salts of isomers is possible within the  
21 specific chemical designation:

- 22 (1) Diethylpropion;
- 23 (2) Phentermine;
- 24 (3) Pemoline, including organometallic complexes and chelates  
25 thereof;
- 26 (4) Mazindol;
- 27 (5) Pipradrol;
- 28 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 29 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
- 30 (8) Fencamfamin;
- 31 (9) Fenproporex;

1 (10) Mefenorex;

2 (11) Modafinil; and

3 (12) Sibutramine.

4 (d) Unless specifically excepted or unless listed in another  
5 schedule, any material, compound, mixture, or preparation which contains  
6 any quantity of the following narcotic drugs, or their salts or isomers  
7 calculated as the free anhydrous base or alkaloid, in limited quantities  
8 as set forth below:

9 (1) Propoxyphene in manufactured dosage forms;

10 (2) Not more than one milligram of difenoxin and not less than  
11 twenty-five micrograms of atropine sulfate per dosage unit; and

12 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its  
13 salts, optical and geometric isomers, and salts of these isomers to  
14 include: Tramadol.

15 (e) Unless specifically excepted or unless listed in another  
16 schedule, any material, compound, mixture, or preparation which contains  
17 any quantity of the following substance, including its salts:

18 (1) Pentazocine; and

19 (2) Butorphanol (including its optical isomers).

20 (f) Any material, compound, mixture, or preparation which contains  
21 any quantity of the following substances, including its salts, isomers,  
22 and salts of such isomers, whenever the existence of such salts, isomers,  
23 and salts of isomers is possible: Lorcaserin.

24 (g)(1) Unless specifically excepted or unless listed in another  
25 schedule, any material, compound, mixture, or preparation which contains  
26 any quantity of the following substance, including its salts, optical  
27 isomers, and salts of such optical isomers: Ephedrine.

28 (2) The following drug products containing ephedrine, its salts,  
29 optical isomers, and salts of such optical isomers, are excepted from  
30 subdivision (g)(1) of Schedule IV if they (A) are stored behind a  
31 counter, in an area not accessible to customers, or in a locked case so

1 that a customer needs assistance from an employee to access the drug  
2 product; (B) are sold by a person, eighteen years of age or older, in the  
3 course of his or her employment to a customer eighteen years of age or  
4 older with the following restrictions: No customer shall be allowed to  
5 purchase, receive, or otherwise acquire more than three and six-tenths  
6 grams of ephedrine base during a twenty-four-hour period; no customer  
7 shall purchase, receive, or otherwise acquire more than nine grams of  
8 ephedrine base during a thirty-day period; and the customer shall display  
9 a valid driver's or operator's license, a Nebraska state identification  
10 card, a military identification card, an alien registration card, or a  
11 passport as proof of identification; (C) are labeled and marketed in a  
12 manner consistent with the pertinent OTC Tentative Final or Final  
13 Monograph; (D) are manufactured and distributed for legitimate medicinal  
14 use in a manner that reduces or eliminates the likelihood of abuse; and  
15 (E) are not marketed, advertised, or represented in any manner for the  
16 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or  
17 high, heightened sexual performance, or increased muscle mass:

- 18 (i) Primatene Tablets; and  
19 (ii) Bronkaid Dual Action Caplets.

20 Schedule V

21 (a) Any compound, mixture, or preparation containing any of the  
22 following limited quantities of narcotic drugs or salts calculated as the  
23 free anhydrous base or alkaloid, which shall include one or more  
24 nonnarcotic active medicinal ingredients in sufficient proportion to  
25 confer upon the compound, mixture, or preparation valuable medicinal  
26 qualities other than those possessed by the narcotic drug alone:

- 27 (1) Not more than two hundred milligrams of codeine per one hundred  
28 milliliters or per one hundred grams;  
29 (2) Not more than one hundred milligrams of dihydrocodeine per one  
30 hundred milliliters or per one hundred grams;  
31 (3) Not more than one hundred milligrams of ethylmorphine per one

1 hundred milliliters or per one hundred grams;

2 (4) Not more than two and five-tenths milligrams of diphenoxylate  
3 and not less than twenty-five micrograms of atropine sulfate per dosage  
4 unit;

5 (5) Not more than one hundred milligrams of opium per one hundred  
6 milliliters or per one hundred grams; and

7 (6) Not more than five-tenths milligram of difenoxin and not less  
8 than twenty-five micrograms of atropine sulfate per dosage unit.

9 (b) Unless specifically exempted or excluded or unless listed in  
10 another schedule, any material, compound, mixture, or preparation which  
11 contains any quantity of the following substances having a stimulant  
12 effect on the central nervous system, including its salts, isomers, and  
13 salts of isomers: Pyrovalerone.

14 (c) Unless specifically exempted or excluded or unless listed in  
15 another schedule, any material, compound, mixture, or preparation which  
16 contains any quantity of the following substances having a depressant  
17 effect on the central nervous system, including its salts, isomers, and  
18 salts of isomers:

19 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic  
20 acid ethyl ester);

21 (2) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);  
22 and

23 (3) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid); and

24 (4) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]  
25 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its  
26 salts.

27 (d) Cannabidiol in a drug product approved by the federal Food and  
28 Drug Administration.

29 Sec. 2. Original section 28-405, Revised Statutes Supplement, 2017,  
30 is repealed.